Cat. No.: DAB-0012623
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr194 of human Prdx1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PRDX1 |
| UniProt No. | Q06830 |
| Gene ID | 5052 |
| Gene Description | Prdx1 belongs to a family of non-seleno peroxidases that function as H2O2 scavengers. All 6 Prdx isoforms share a conserved N-terminal cysteine that is oxidized by H2O2 to form cysteine-sulfenic acid and, in turn, reacts with Cys172-SH of another Prdx protein, forming a disulfide dimer and protecting it from degradation. Abnormally high levels of H2O2 cause Prdx1 to form an oligomeric chaperone that loses its peroxidase activity. Prdx family members have been reported to bind to JNK and c-Abl and regulate their kinase activity. Prdx1 was shown to bind to PTEN and regulate its phosphatase activity in conditions of mild or no cellular stress, hence preventing Akt-driven transformation by protecting PTEN from oxidation-induced inactivation.The transient phosphorylation of Prdx1 at Tyr194 leads to inactivation of Prdx1 that in turn promotes localized hydrogen peroxide accumulation. Evidence suggests that the Tyr194 phosphorylation of Prdx1 is prominent at the wound edge during repair of cutaneous injury in mice. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
